
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Antigenics Inc. has announced its experimental cancer vaccine Oncophage improved post-surgery results for patients with metastatic melanoma, with one of 18 patients remaining disease-free for almost 15 months.






